Cargando…
Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is the most common type of dementia. Although a considerably large amount of money has been invested in drug development for AD, no disease modifying treatment has been detected so far. In our previous work, we developed a compu...
Autores principales: | Savva, Kyriaki, Zachariou, Margarita, Kynigopoulos, Demos, Fella, Eleni, Vitali, Maria-Ioanna, Kosofidou, Xeni, Spyrou, Michail, Sargiannidou, Irene, Panayiotou, Elena, Dietis, Nikolas, Spyrou, George M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221567/ https://www.ncbi.nlm.nih.gov/pubmed/37240740 http://dx.doi.org/10.3390/life13051095 |
Ejemplares similares
-
Network-based stage-specific drug repurposing for Alzheimer’s disease
por: Savva, Kyriaki, et al.
Publicado: (2022) -
Vir2Drug: a drug repurposing framework based on protein similarities between pathogens
por: Minadakis, George, et al.
Publicado: (2022) -
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19
por: Tomazou, Marios, et al.
Publicado: (2021) -
PathwayConnector: finding complementary pathways to enhance functional analysis
por: Minadakis, George, et al.
Publicado: (2019) -
Selecting variants of unknown significance through network-based gene-association significantly improves risk prediction for disease-control cohorts
por: Oulas, Anastasis, et al.
Publicado: (2019)